FDA Approval

The FDA has approved neffy® 1mg epinephrine nasal spray for children weighing 33 to 66 pounds, marking a major breakthrough in needle-free anaphylaxis treatment. This approval eliminates the fear of needle-based auto-injectors, providing a fast, easy-to-use, and effective alternative for treating severe allergic reactions. neffy® is expected to be available in the U.S. by May 2025, with financial assistance programs ensuring accessibility for families. This innovation could significantly improve emergency response and health outcomes for children with food allergies.

The introduction of neffy® nasal spray marks a significant advancement in the treatment of severe allergic reactions, offering a needle-free, easy-to-use alternative to traditional epinephrine auto-injectors. Now available nationwide, neffy provides a safe and convenient option for individuals at risk of anaphylaxis, ensuring faster and more effective treatment.

In a monumental step forward for allergy treatment, the FDA has approved neffy, the first-ever nasal spray for the emergency treatment of anaphylaxis. This needle-free alternative offers a life-saving option for those with severe allergies, particularly benefiting individuals who may delay treatment due to a fear of injections. Learn more about this groundbreaking advancement and how it can change the way allergic reactions are treated.